Treatment with glucocorticoids or calcineurin inhibitors in primary FSGS

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 3, 2016, Pages 386-394

  Laurin, Louis Philippe ^a,b,c,d   Gasim, Adil M ^c   Poulton, Caroline J ^c   Hogan, Susan L ^c   Charles Jennette, J ^c   Falk, Ronald J ^c   Foster, Bethany J ^c,d,e,f   Nachman, Patrick H ^c  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e MONTREAL CHILDREN S HOSPITAL   (Canada)

^f RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; MYCOPHENOLATE MOFETIL; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CHILD; DRUG EFFICACY; DRUG MEGADOSE; EDEMA; END STAGE RENAL DISEASE; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADOLESCENT; CHI SQUARE DISTRIBUTION; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; CALCINEURIN INHIBITORS; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960157865     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07110615     Document Type: Article

References (32)

1. Haas M, Meehan SM, Karrison TG, Spargo BH: Changing etiologies of unexplained adult nephrotic syndrome: A comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 30: 621–631, 1997.
2. Kitiyakara C, Eggers P, Kopp JB: Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 44: 815–825, 2004.
3. D’Agati VD, Kaskel FJ, Falk RJ: Focal segmental glomerulosclerosis. N Engl J Med 365: 2398–2411, 2011.
4. Korbet SM, Schwartz MM, Lewis EJ: Primary focal segmental glomerulosclerosis: Clinical course and response to therapy. AmJ Kidney Dis 23: 773–783, 1994.
5. Banfi G, Moriggi M, Sabadini E, Fellin G, D’Amico G, Ponticelli C: The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 36: 53–59, 1991.
6. Cattran DC, Rao P: Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. AmJ KidneyDis 32: 72–79, 1998.
7. Rydel JJ, Korbet SM, Borok RZ, Schwartz MM: Focal segmental glomerular sclerosis in adults: Presentation, course, and response to treatment. Am J Kidney Dis 25: 534–542, 1995.
8. Braun N, Schmutzler F, Lange C, Perna A, Remuzzi G, Risler T, Willis NS: Immunosuppressive treatment for focal segmental glomerulosclerosis in adults.CochraneDatabase Syst Rev 3:CD003233, 2008.
9. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL; North AmericaNephrotic Syndrome Study Group: A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. Kidney Int 56: 2220–2226, 1999.
10. Lieberman KV, Tejani A: A randomized double-blind placebocontrolled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 7: 56–63, 1996.
11. Hodgin JB, Rasoulpour M, Markowitz GS, D’Agati VD: Very low birth weight is a risk factor for secondary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 4: 71–76, 2009.
12. Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD: Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 59: 1498–1509, 2001.
13. Herlitz LC, Markowitz GS, Farris AB, Schwimmer JA, Stokes MB, Kunis C, Colvin RB, D’Agati VD: Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J AmSoc Nephrol 21: 163–172, 2010.
14. Bhathena DB, Julian BA, McMorrow RG, Baehler RW: Focal sclerosis of hypertrophied glomeruli in solitary functioning kidneys of humans. Am J Kidney Dis 5: 226–232, 1985.
15. Harvey JM, Howie AJ, Lee SJ, Newbold KM, Adu D, Michael J, Beevers DG: Renal biopsy findings in hypertensive patients with proteinuria. Lancet 340: 1435–1436, 1992.
16. D’Agati V: Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 23: 117–134, 2003.
17. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114[2 Suppl 4th Report]: 555–576, 2004.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate fromserumcreatinine: A new prediction equation. Ann Intern Med 130: 461–470, 1999.
19. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL: New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20: 629–637, 2009.
20. Rothman KJ, Greenland S, Lash TL: Modern Epidemiology, 3rd Ed., Philadelphia, Lippincott Williams & Wilkins, 2008.
21. Ginsberg JM, Chang BS, Matarese RA, Garella S: Use of single voided urine samples to estimate quantitative
22. Hoes JN, Jacobs JW, Verstappen SM, Bijlsma JW, Van der Heijden GJ: Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: A meta-analysis. Ann Rheum Dis 68: 1833–1838, 2009.
23. Anonymous: Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults. Kidney Int Suppl (2011) 2: 181–185, 2012.
24. Stokes MB, Markowitz GS, Lin J, Valeri AM, D’Agati VD: Glomerular tip lesion: A distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum. Kidney Int 65: 1690–1702, 2004.
25. Chitalia VC, Wells JE, Robson RA, Searle M, Lynn KL: Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int 56: 2236–2242, 1999.
26. Cameron JS, Turner DR, Ogg CS, Chantler C, Williams DG: The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 10: 213–218, 1978.
27. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group: Focal and segmental glomerulosclerosis: Definition and relevance of a partial remission. J Am Soc Nephrol 16: 1061–1068, 2005.
28. Stokes MB, Valeri AM, Markowitz GS, D’Agati VD: Cellular focal segmental glomerulosclerosis: Clinical and pathologic features. Kidney Int 70: 1783–1792, 2006.
29. Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Hladunewich M, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, Nachman PH, Reich HN: Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol 7: 43–51, 2012.
30. Mace´ C, Chugh SS: Nephrotic syndrome: Components, connections, and angiopoietin-like 4-related therapeutics. J AmSoc Nephrol 25: 2393–2398, 2014.
31. Xie J, Kiryluk K, Wang W, Wang Z, Guo S, Shen P, Ren H, Pan X, Chen X, Zhang W, Li X, Shi H, Li Y, Gharavi AG, Chen N: Predicting progression of IgAnephropathy: Newclinical progression risk score. PLoS One 7: e38904, 2012.
32. Austin PC: A tutorial and case study in propensity score analysis: An application to estimating the effect of in-hospital smoking cessation counseling on mortality. Multivariate Behav Res 46: 119–151, 2011